ReviewFrontiers in bioinformatics2026
AI-driven discovery in protein science for immunology and infectious disease research.
Review in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence as a Discovery Engine for Routine Molecular Techniques: Extracting Biological Insight from Western Blotting, ELISA, Immunostaining, and Immunoprecipitation.Cell biochemistry and biophysics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial Intelligence (AI) is impacting several aspects of modern life with its ability to enhance decision-making, automate complex tasks, and generate human-like content. It is now an indispensable tool in both everyday life and academic inquiry. In particular, the rapid evolution of AI technologies, especially machine learning, deep learning, and natural language processing (NLP), has given rise to large language models (LLMs), which have transformed how we analyze, interpret, and generate text-based, structured data and unstructured data. Among these, Generative AI (GenAI) has become increasingly popular due to its capacity to create content ranging from text and code to protein sequences and molecular structures, all based on patterns found in large training datasets. GenAI tools can assist with literature reviews, writing support, data processing, hypothesis generation, and code or visualization tasks, although outputs require critical oversight to ensure accuracy and relevance. More advanced GenAI applications include the generation of synthetic data and even the design of biological molecules and materials. Within this broader context, the fields of immunology, vaccinology, and infectious diseases research are witnessing a wave of innovation driven by AI. In this review, we explore how these recent advances in GenAI, especially those based on LLMs, are being applied to immunological research, antibody design, vaccine development, infectious diseases research and pandemic preparedness. This review is structured as a scoping review, aiming to map the rapidly evolving applications of GenAI and LLMs in immunology, vaccine development, infectious disease research, and adjacent biomedical fields. Relevant studies were identified through searching PubMed, Google Scholar and preprint archives and included if they introduced, demonstrated, or benchmarked AI-based approaches with clear relevance to immunology and infectious disease, while older preprints without subsequent peer-reviewed publication were excluded. We aim to provide a comprehensive overview of current contributions, emerging tools and models, and future perspectives of GenAI in transforming how we understand and manipulate immune responses and infectious diseases. Therefore, the reported capabilities should be interpreted as indicative of potential rather than definitive performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.